NRC Health’s Q3 2026: Recurring Revenue Grows, EPS Keeps Pace, and a Dividend Keeps the Lights On

NRC Health, ticker NRC, reports third-quarter 2026 results—EPS, revenue, and a cash dividend in focus as the company leans into its recurring-revenue model.

Overview: a quarter of growth and cash flow, with a dividend to boot

NRC Health (NASDAQ: NRC) disclosed third-quarter 2026 results that reinforce a business built on recurring-customer relationships. Revenue reached $38.4 million, up 11% from the prior year, while Total Recurring Contract Value (TRCV) climbed to $154.1 million, up 9% year over year. On the bottom line, GAAP net income was $4.7 million, representing roughly 12% of revenue, and EPS came in at $0.21 on 22.0 million fully diluted shares.

The company also highlighted Adjusted EBITDA of $10.9 million, or about 28% of revenue, and free cash flow of $7.0 million, underscoring a business that translates growth into cash generation. In addition, the Board declared a quarterly cash dividend of $0.16 per share, payable January 8, 2027, with a record date of December 29, 2026.

Key highlights and metrics

Revenue: $38.4 million for the quarter; up 11% year over year
TRCV: $154.1 million; up 9% year over year
Net Income (GAAP): $4.7 million; 12% of revenue
EPS: $0.21 on 22.0 million fully diluted shares
Adjusted EBITDA: $10.9 million; 28% of revenue
Free Cash Flow: $7.0 million
Dividend Declaration: $0.16 per share; payable Jan 8, 2027

The release also reiterates the use of non-GAAP financial measures and highlights the importance of Total Recurring Contract Value as a metric for durability of the revenue stream.

Non-GAAP measures and TRCV as a guide to durability

NRC Health points to Non-GAAP Financial Measures and explains Total Recurring Contract Value as a key metric. Reconciliations of the non-GAAP measures to the closest GAAP figures are included in the tables of the release. The emphasis on TRCV mirrors a broader investor preference for recurring revenue signals in the health‑tech services space, where long-term contracts can provide visibility beyond quarterly noise.

Analysis: what this portends for NRC Health and peers

The quarter reads like a practical demonstration of the company’s thesis: large customers go live as scheduled, renewals accumulate under multi-year terms, and operating leverage emerges as revenue expands. The CEO’s quote underscores this: as the contract base scales, the model should translate into stronger profitability and free cash flow over time.

From an earnings-visibility standpoint, the EPS figure of $0.21 on 22.0 million shares is notable for stability given a modest GAAP net margin, but the headline is the trajectory: revenue growth, a growing TRCV base, and meaningful cash generation. In markets where earnings surprise and EPS consensus drive reactions, NRC’s results—paired with a steady, shareholder-friendly dividend—could set a precedent for peers that rely on multi-year contracts and renewals.

A potential takeaway for sector peers is the emphasis on recurring revenue versus one-off deals. As customers become embedded in NRC Health’s platform, the pricing framework and renewal dynamics may accelerate revenue forecast stability—assuming churn remains contained and new logo momentum sustains the current pace.

Dividend and capital allocation: signaling confidence

The quarterly dividend of $0.16 per share signals a commitment to returning capital while preserving growth options. In a market where some health-tech providers burn cash to fund expansion, NRC Health appears to balance cash generation with shareholder rewards. The January 2027 payment date provides a tangible timeline for investors watching dividend growth alongside EPS and revenue forecast projections.

Outlook for NRC Health and the sector

With Q3 cash flow engines running and a durable TRCV base, NRC Health may be positioned to weather slower macro cycles better than firms relying on one-off projects. The absence of explicit forward-looking guidance in this release means investors will likely map the quarter to upcoming conference calls or guidance updates for finer clarity on the revenue forecast trajectory and potential earnings surprise risk or opportunity.

For sector peers—providers of healthcare experience improvement solutions—the lesson is twofold: maintain transparency around non-GAAP metrics, and demonstrate how contract longevity translates into cash generation. In a space where EPS consensus can swing on small changes in renewal rates and cadence of new deals, NRC Health’s Q3 print delivers a blueprint of how to talk about growth without overstating it.